Analyst Upgrades

• Bunge (BG) to buy from hold at Deutsche Bank.
• Textron (TXT) to overweight from neutral at JPMorgan.
• CSX (CSX) to buy from neutral and Pulte Group (PHM) to conviction buy from neutral at Goldman.
• Aol (AOL) to buy from neutral at UBS.
• Kohlberg Capital (KCAP) to outperform from market perform at JMP Securities.
• Owens Corning (OC) to buy from neutral at BofA/Merrill.
• Jefferies (JEF) to buy from neutral at Ticonderoga.
• Harris (HRS) to outperform from perform at Oppenheimer.

Analyst Upgrades

• Google (GOOG) to outperform from neutral at Wedbush.
• Nike (NKE) to buy from neutral at UBS.
• Apollo Group (APOL) to market perform from underperform at FBR Capital.
• JDSU (JDSU) to overweight from neutral at Piper Jaffray.
• NetApp (NTAP) to overweight from equal weight and Verigy (VRGY) to equal weight from underweight at Barclays.
• RSC Holdings (RRR) to outperform from neutral at RW Baird.
• Exelon (EXC) to buy from hold at Jefferies.
• Aon (AON) and Willis Group (WSH) to outperform from market perform at Keefe Bruyette.
• BMC Software (BMC) to outperform from neutral at Cowen.

Analyst Upgrades

• Piper Jaffray upgraded Red Hat (RHT) to overweight from neutral.
• Honeywell (HON) was upgraded to outperform from neutral at Cowen.
• Regal-Beloit (RBC) and Actuant (ATU) were upgraded to buy from hold at Jefferies.
• RW Baird upgraded MedAssets (MDAS) to outperform from neutral.
• Savvis (SVVS) was upgraded to outperform from market perform at William Blair.

Analyst Upgrades

• KeyBanc upgraded Las Vegas Sands (LVS) to hold from underweight based on Singapore performance and a potential revaluation of the yuan.
• ThinkEquity upgraded Seattle Genetics (SGEN) to buy from hold based on the positive SGN-35 HL data. The firm raised its price target to $16 from $12.
• Merriman upgraded Applied Signal (APSG) to buy from neutral with a $28 to $31 valuation range, citing greater confidence in earnings estimates and the company's recent contract wins.
• Siliconware Precision (SPIL) was upgraded to neutral from underperform at Macquarie.
• Pulte Group (PHM) was upgraded to neutral from sell at Goldman.
• Greenbrier (GBX) was upgraded to outperform from market perform at Morgan Keegan.

Analyst Upgrades

• Auriga upgraded Allscripts (MDRX) to buy from hold to reflect valuation and potential synergies from the company's pending merger with Eclipsys (ECLP). The firm upped its target price for shares to $20 from $19.
• SunTrust upgraded Newell Rubbermaid (NWL) to buy from neutral based on completion of its turnaround plan, stabilizing end markets and favorable comparisons. The firm has a $25 price target on the stock.
• Morgan Joseph upgraded C.R. Bard (BCR) to buy from hold based on valuation and upside to estimates from the share buyback program. The firm has a $97 price target on the stock.
• Shire (SHPGY) was upgraded to buy from hold at Lazard Capital.
• Onyx Pharma (ONXX) was upgraded to outperform from market perform at BMO Capital.
• AvalonBay (AVB) was upgraded to neutral from sell at UBS.

Analyst Upgrades

• Piper Jaffray upgraded Psychiatric Solutions (PSYS) to neutral from underweight on expectations the company's merger with Universal Health (UHS) will close.
• Jefferies upgraded Intuit (INTU) to buy from neutral and has a $45 price target on the stock. The firm expects Intuit's 2011 tax season to be at least as good as 2010's and sees improvement in the SMB exposed businesses.
• Wells Fargo upgraded Unica (UNCA) to outperform from market perform. The firm upgraded the stock due to what it sees as improving trends in marketing spending, upcoming enhancements in the company's products and long-term opportunity for marketing software to exceed expectations.
• Textron (TXT) was upgraded to conviction buy from buy at Goldman.
• RightNow (RNOW) was upgraded to outperform from market perform at FBR Capital.
• Beazer Homes (BZH) was upgraded to buy from hold at Citigroup.

TheStreet.com's Jim Cramer says that from a chart perspective, this could be about the greatest bull market in history.

Chart to chart to chart this weekend and all I see, except for a couple of health maintenance, medical device and drug companies plus some fertilizer stocks, is just a remarkable and, yes, unheralded run in every single group.

Some of them are of the pure recovery style: every oil and gas, now including refinery, as the crude price inches back to $100 and natural gas has started its way back up; the life insurers that were left for dead when we decided that all commercial mortgages would be destroyed taking them with the bad loans; the overly-indebted companies like Textron (NYSE: TXT) (Cramer's Take) that have roared back without any real support from anyone.

But others are just monumental. Anything paper or wood or glass. These aren't quitting.

Analyst upgrades:

• Citigroup upgraded Cooper Industries (NYSE: CBE) to Buy from Hold on valuation as it believes commercial construction concerns are well known. The firm raised its target on shares to $40 from $37, and coupled the upgrade with a downgrade of Rockwell Automation (NYSE: ROK) to Sell from Hold.
• Credit Suisse upgraded BJ Services (NYSE: BJS) to Neutral from Underperform following its acquisition by Baker Hughes (NYSE: BHI). The firm raised its target to $17.
• Credit Suisse also upgraded Amkor Technology (NASDAQ: AMKR) to Outperform from Neutral and raised its target to $8 from $7. The firm expects Amkor to benefit from near-term strength in the supply chain and the mix shift towards higher value packaging.
• Textron (NYSE: TXT) was upgraded to Conviction Buy from Neutral at Goldman.
• Siemens (NYSE: SI) was upgraded to Neutral from Sell at UBS.
• Stanley Works (NYSE: SWK) was upgraded to Buy from Neutral at Janney Montgomery.

Analyst upgrades:

• Citigroup upgraded American Express (NYSE: AXP) to Buy from Hold and added the stock to its Top Picks Live list following the company's investor day. Citi believes American Express' credit trends are improving and raised its price target on shares to $36 from $28.
• Janney Montgomery upgraded Gardner Denver (NYSE: GDI) to Buy from Neutral after meeting with management to reflect expectations for EPS growth in 2010 and valuation. The firm has a $38 target on the stock.
• BofA/Merrill upgraded Freeport McMoRan (NYSE: FCX) to Buy from Underperform and raised its target to $87 from $49 based on strong copper fundamentals.
• Cbeyond (NASDAQ: CBEY) was upgraded to Overweight from Equal Weight at Stephens.
• Gibraltar Industries (NASDAQ: ROCK) was upgraded to Outperform from Neutral at Baird.
• Fortress (NYSE: FIG) was upgraded to Outperform from Market Perform at Keefe Bruyette.

Three products that are probably bad bets in this environment are private jets, helicopters and golf carts. Add in a large captive finance arm and an auto parts unit and you have Textron (NYS: TXT), the latest hobgoblin to join the dividend slasher parade and corporate Deathwatch. The Piqqem Sentiment on Textron is hard negative. The good folks at Ockham's Research hammer home these points and more.

Textron has had trouble in the past accessing commercial paper markets (and it's surely not having trouble now, right?) and raising equity capital. More than 50% of the assets on the books of its captive finance arm are non-performing and that could worsen as more companies that owe it money start to tip over in the various blighted industries it services. Add a slashed dividend to spook value and institutional investors. The upshot? Textron is basically ready to keel over, unfortunately.

TheStreet.com's Jim Cramer says stocks are headed lower, perhaps much lower, even if the banks receive the help they need.

You can see it dawn on people one by one. We aren't coming out of this morass, we are just going into it. The president and Congress aren't serious about it. But more importantly, somehow, the companies are stunned by it.

If you want to read about what it is like to recognize that things are falling apart, go read the Textron (NYSE: TXT) (Cramer's Take) quarter. They actually thought there would be some improvement at year-end. That's not going to happen to a Cessna manufacturer with a commercial finance division of dubious worth. Perhaps there was some hyperbole, but Textron said it was the worst manufacturing time ever!

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Accenture Ltd. (NYSE: ACN) reported strong Q1 numbers as its clients sought ways to cut costs.
• Best Buy Inc. (NYSE: BBY) may interest short sellers despite its earnings prospects for 2009.
• International Paper Co. (NYSE: IP) to shed dead wood to reduce the impact of the recession on earnings.
• Manpower Inc. (NYSE: MAN) withdrew Q4 profit and revenue guidance, sending shares lower.
• Textron Inc. (NYSE: TXT) lowered its Q4 earnings forecast to well below analysts' estimates.
• Toyota Motor Corp. (NYSE: TM) forecast its first-ever loss for the fiscal year on lower demand/higher yen.
• Walgreen Co. (NYSE: WAG) missed Q1 expectations and announced cost cutting and store redesign.

Also, bank earnings will be hit next by cancelled M&A deals.

Earnings releases scheduled for early January include Navistar (NYSE: NAV), Bed Bath & Beyond (NASDAQ: BBBY), Constellation Brands (NYSE: STZ), Family Dollar (NYSE: FDO), and Monsanto (NYSE: MON).

Visit AOL Money & Finance for more earnings coverage.

Textron (NYSE: TXT - option chain), the aircraft company that makes Cessna and Bell, among others, is down steeply today after the company cut its fourth-quarter adjusted EPS forecast to 30 cents to 40 cents, from a previous estimate of 80 cents to 90 cents. Analysts are expecting an adjusted profit of 83 cents per share. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on TXT.

This morning, TXT opened at $13.55. So far today the stock has hit a low of $12.13 and a high of $14.35. As of 3:34. TXT is trading at $12.27, down $3.11 (-20. 27%). The chart for TXT looks bullish and S&P gives TXT a positive 4 STARS (out of 5) buy ranking.

For a bearish hedged play on this stock, I would consider a February bear-call credit spread above the $17.50 range. A bear-call credit spread is an options position that combines the purchase and sale of call options to hedge risk in case the stock doesn't do what you think but still leverage nice returns. For this particular trade, we will make an 8.7% return in four months as long as TXT is below $17.50 at February expiration. Textron would have to rise by more than 41% before we would start to lose money.

TXT hasn't been above $17.50 since early November and shown resistance around $16 recently.

Brent Archer is an options analyst and writer at Investors Observer. At publication time, Brent neither owns nor controls positions in TXT.

Analyst upgrades:

• Goldman upgraded shares of BP Plc (NYSE: BP) to Buy from Neutral on valuation as they believe the recent pullback provides an attractive entry point.
  
• VF Corp. (NYSE: VFC) was raised to Outperform from Neutral at Credit Suisse citing its acquisition platform and international growth. The company's target was increased to $100 from $88.
  
• Deutsche Bank upgraded shares of Tenet Healthcare (NYSE: THC) to Buy from Hold and increased its target to $8.50 from $7 to reflect increased confidence in the company's ability to beat expectations over the next 12 months and reduce its net debt.
• US Steel (NYSE: X) was raised to Sector Outperformer from Sector Performer at CIBC.
  
• United Technologies (NYSE: UTX) was upgraded at UBS to Buy from Neutral.

Analyst downgrades:

MOST NOTEWORTHY: Stanley Works, the Generic Drug sector, Fiserv and Fidelity National were today's noteworthy downgrades:

• Deutsche Bank downgraded shares of Stanley Works (NYSE: SWK) to Hold from Buy as they see risk to Q2 and FY08 earnings due to a slowdown in the European industrial and consumer categories. The firm lowered their target to $52 from $62.
  
• Wachovia cut the Generic Drug sector to Market Weight from Overweight Wachovia sees near-term challenges for Teva Pharmaceutical (NASDAQ: TEVA), Mylan (NYSE: MYL) and Watson Pharmaceuticals (NYSE: WPI). The firm thinks Teva will become a very strong company over the long-term, following its takeover of Barr (NYSE: BRL). However, the firm adds that Teva will need to integrate the acquisition nearly perfectly, and Mylan may feel compelled to make another acquisition, even as it is still integrating Merck Generics, while Watson's growth prospects are still uncertain.
  
• Oppenheimer downgraded Fiserv (NASDAQ: FISV) and Fidelity National (NYSE: FIS) to Perform from Outperform based on multiple pressure from the challenging banking environment and growth headwinds.

OTHER DOWNGRADES:

• Satyam (NYSE: SAY) was downgraded to Underperform from Outperform at Credit Suisse and Equal Weight from Overweight at Morgan Stanley.
  
• UBS downgraded Textron (NYSE: TXT) to Neutral from Buy.
  
• Constellation Energy (NYSE: CEG) was downgraded at Jefferies to Underperform from Hold.